bpc 157 cancer risk evidence BPC-157 And TB-500: Background, Indications, Efficacy, And Safety GlobalRPH Columbia Undergraduate Science Journal
Description
10.1021/acssynbio.6b00364
Available online at: (Accessed September 30, 2015)
This approach is especially useful for targets with a relatively short cellular half-life as (proteasomal/proteolytic) degradation of the protein target will induce the release of the reversibly bound covalent inhibitor that can engage in the inhibition of another target protein
Beyond a certain point, receptor saturation means diminishing returns
For help setting up these specialized protocols, see creating-a-sterile-research-environment-2
